Vaccinex (NASDAQ:VCNX) Stock Price Down 4.5% – Here’s Why

Shares of Vaccinex, Inc. (NASDAQ:VCNX) dropped 4.5% during mid-day trading on Monday . The stock traded as low as $1.00 and last traded at $1.05. 5,075 shares traded hands during trading, an increase of 57% from the average daily volume of 3,241 shares. The stock had previously closed at $1.10.

Vaccinex Price Performance

The stock has a market cap of $1.86 million, a price-to-earnings ratio of -0.01 and a beta of 1.10. The business’s fifty day simple moving average is $1.06 and its 200 day simple moving average is $1.04.

Vaccinex Company Profile

Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.

In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.